Novartis: FDA approves new oral multiple sclerosis drug
(CercleFinance.com) - US regulators have approved a new multiple sclerosis orally administered drug made by Novartis for the treatment of adults with relapsing forms of the disease.
The Food and Drug Administration has approved Mayzent for the treatment of secondary progressive multiple sclerosis with active disease, relapsing remitting multiple sclerosis and clinically isolated syndrome.
Secondary progressive multiple sclerosis is a debilitating form of multiple sclerosis that is characterized by progressive and irreversible neurological disability.
Mayzent is expected to be available in the US in about one week, Novartis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Food and Drug Administration has approved Mayzent for the treatment of secondary progressive multiple sclerosis with active disease, relapsing remitting multiple sclerosis and clinically isolated syndrome.
Secondary progressive multiple sclerosis is a debilitating form of multiple sclerosis that is characterized by progressive and irreversible neurological disability.
Mayzent is expected to be available in the US in about one week, Novartis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.